Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Clinical evaluation of Tc-99m N,N'-bis(mercaptoacetyl)-2,3-diaminopropanoate as a replacement for I-131 hippurate: concise communication

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:5442520
A clinical comparison of Tc-99m N,N'-bis(mercaptoacetyl)-2,3-diaminopropanoate (Component A) (Tc-99m CO/sub 2/-DADS-A) and I-131 hippurate was conducted in a series of five normal volunteers and 18 patients. Each subject was studied in one session with Tc-99m CO/sub 2/-DADS-A and I-131-hippurate; digital and analog images were recorded for 30 min and after voiding. In the normal volunteers, digital images with Tc-99m CO/sub 2/-DADS-A gave a kidney-to-background ratio at 3 min that was greater relative to I-131 hippurate, a leading-edge parenchymal transit time that was similar to I-131 hippurate, and a percent injected dose in the urine at 30 min that was slightly less than I-131 hippurate (p<0.05). In patients (serum creatinine 1.0 to 14.3 mg/dl), deceasing renal function impaired excretion of Tc-99m CO/sub 2/-DADS-A more than that of I-131 hippurate (p < 0.01). In analog images, Tc-99mCO/sub 2/-DADS-A always gave superior spatial resolution. No evidence of hepatobiliary excretion was detected with either radiopharmaceutical. The authors conclude that Tc-99m CO/sub 2/-DADS-A and similar compounds should be pursued as possible replacements for I-131 hippurate
Research Organization:
Univ. of Colorado Health Sciences Center, Denver, CO
OSTI ID:
5442520
Journal Information:
J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 25:1; ISSN JNMEA
Country of Publication:
United States
Language:
English